Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients

Although crizotinib has demonstrated promising efficacy and acceptable toxicity in patients with advanced non‐small cell lung cancer (NSCLC), the available evidence in Chinese populations is currently limited. This study compared the progression‐free survival (PFS) of Chinese patients with anaplasti...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Med
Main Authors: Cui, Shaohua, Zhao, Yizhuo, Dong, Lili, Gu, Aiqin, Xiong, Liwen, Qian, Jialin, Zhang, Wei, Niu, Yanjie, Pan, Feng, Jiang, Liyan
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2016
Subjects:
Clinical Cancer Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4924358/
https://ncbi.nlm.nih.gov/pubmed/26880708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.659
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items